130 related articles for article (PubMed ID: 27129437)
1. Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents.
Abdel-Rahman O; ElHalawani H
Crit Rev Oncol Hematol; 2016 Jun; 102():89-100. PubMed ID: 27129437
[TBL] [Abstract][Full Text] [Related]
2. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H
Expert Opin Drug Saf; 2015 Oct; 14(10):1495-506. PubMed ID: 26313327
[TBL] [Abstract][Full Text] [Related]
3. Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis.
Abdel-Rahman O; ElHalawani H
Chemotherapy; 2014; 60(5-6):325-33. PubMed ID: 26302785
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
Qi WX; Fu S; Zhang Q; Guo XM
J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
[TBL] [Abstract][Full Text] [Related]
5. Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.
Abdel-Rahman O; ElHalawani H
Future Oncol; 2015; 11(21):2949-61. PubMed ID: 26422782
[TBL] [Abstract][Full Text] [Related]
6. Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis.
Tian R; Yan H; Zhang F; Sun P; Zheng X; Zhu Y; Wang Q; He J
Oncotarget; 2016 Oct; 7(40):66182-66191. PubMed ID: 27507055
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
[TBL] [Abstract][Full Text] [Related]
8. Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Curr Med Res Opin; 2015 May; 31(5):975-86. PubMed ID: 25708852
[TBL] [Abstract][Full Text] [Related]
9. Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Opin Drug Saf; 2014 Aug; 13(8):999-1008. PubMed ID: 24930544
[TBL] [Abstract][Full Text] [Related]
10. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1063-73. PubMed ID: 24927771
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.
Santoni M; Guerra F; Conti A; Lucarelli A; Rinaldi S; Belvederesi L; Capucci A; Berardi R
Cancer Treat Rev; 2017 Sep; 59():123-131. PubMed ID: 28818671
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials.
Wang K; Qu X; Wang Y; Dong W; Shen H; Zhang T; Ni Y; Liu Q; Du J
Clin Drug Investig; 2016 Jan; 36(1):27-39. PubMed ID: 26547200
[TBL] [Abstract][Full Text] [Related]
13. Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis.
Roviello G; Pacifico C; Corona P; Generali D
Invest New Drugs; 2017 Aug; 35(4):518-523. PubMed ID: 28285368
[TBL] [Abstract][Full Text] [Related]
14. Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.
Wang Z; Zhang J; Zhang L; Liu P; Xie Y; Zhou Q
J Chemother; 2016 Aug; 28(4):328-34. PubMed ID: 26099278
[TBL] [Abstract][Full Text] [Related]
15. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.
Abdel-Rahman O; ElHalawani H; Fouad M
Future Oncol; 2015; 11(17):2471-84. PubMed ID: 26274495
[TBL] [Abstract][Full Text] [Related]
16. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials.
Xiao B; Wang W; Zhang D
Onco Targets Ther; 2018; 11():5059-5074. PubMed ID: 30174444
[TBL] [Abstract][Full Text] [Related]
17. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H; Ahmed H; Ellithy M
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1433-45. PubMed ID: 26365425
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of hypertension with ramucirumab in cancer patients: a meta-analysis of published studies.
Wang J; Wang Z; Zhao Y
Clin Drug Investig; 2015 Apr; 35(4):221-8. PubMed ID: 25697774
[TBL] [Abstract][Full Text] [Related]
19. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Future Oncol; 2014 Oct; 10(12):1981-92. PubMed ID: 25386814
[TBL] [Abstract][Full Text] [Related]
20. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1529-36. PubMed ID: 25159115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
